Background: Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT)
and pulmonary embolism (PE), occurs in∼ 1 to 2 individuals per 1000 each year …

Increasing evidence suggests that renal inflammation contributes to the pathogenesis and
progression of diabetic kidney disease (DKD) and that anti-inflammatory therapies might …

2.1. 1. Epidemiology and burden of the disease. The annual incidence of first episode of
symptomatic DVT in the adult population ranges from 50 to 100 per 100 000 population, with …

Millions of individuals in the United States require long-term treatment with an oral
anticoagulant. For decades, vitamin K antagonists were the only oral option available; …

Importance Incidence rates for lower extremity deep vein thrombosis (DVT) range from 88 to
112 per 100 000 person-years and increase with age. Rates of recurrent VTE range from …

Background: Apixaban and rivaroxaban are replacing vitamin K antagonists for the
treatment of venous thromboembolism (VTE) in adults; however, head-to-head comparisons …

Ibrutinib is a transformative therapy for high-risk and relapsed refractory chronic lymphocytic
leukemia (CLL) patients. In clinical trials in relatively healthy younger patients, ibrutinib has …

Background Apixaban and rivaroxaban, both direct-acting oral anticoagulants, are being
increasingly used in routine clinical practice because of their fixed dosing and favourable …

Nintedanib is a synthetic orally active tyrosine kinase inhibitor, whose main action is to
inhibit the receptors of the platelet-derived growth factor, fibroblast growth factor and …

Deep Vein Thrombosis - Abstract - Europe PMC Sign in | Create an account https://orcid.org
Europe PMC Menu About Tools Developers Help Contact us Helpdesk Feedback Twitter Blog …